Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Research & Development (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Research & Development data on record, last reported at $28.1 million in Q3 2025.

  • For Q3 2025, Research & Development rose 1.48% year-over-year to $28.1 million; the TTM value through Sep 2025 reached $104.9 million, down 24.28%, while the annual FY2024 figure was $111.5 million, 52.35% down from the prior year.
  • Research & Development reached $28.1 million in Q3 2025 per SGMO's latest filing, up from $27.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $66.2 million in Q4 2022 and bottomed at $23.7 million in Q4 2024.
  • Average Research & Development over 5 years is $47.8 million, with a median of $56.4 million recorded in 2021.
  • Peak YoY movement for Research & Development: soared 44.71% in 2021, then tumbled 61.58% in 2024.
  • A 5-year view of Research & Development shows it stood at $51.8 million in 2021, then grew by 27.76% to $66.2 million in 2022, then decreased by 23.38% to $50.7 million in 2023, then tumbled by 53.31% to $23.7 million in 2024, then increased by 18.87% to $28.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $28.1 million in Q3 2025, $27.1 million in Q2 2025, and $26.0 million in Q1 2025.